California dreamin' 'bout endothelin: Emerging new therapeutics

Trends in Pharmacological Sciences

Volumn 17, Issue 5, 1996, Pages 177-181

  Warner, T D ^a   Elliott, J D ^a   Ohlstein, E H ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (N,N DIBUTYLCARBAMOYLMETHYL) 2 (4 METHOXYPHENYL) 4 (3,4 METHYLENEDIOXYPHENYL)PYRROLIDINE 3 CARBOXYLIC ACID; 2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (1,3 BENZODIOXOL 5 YL) 4 CYCLOHEXYLMETHYL 5 HYDROXY 5 (4 METHOXYPHENYL) 2,5 DIHYDROFURAN 2 ONE; 3 (1,3 BENZODIOXOL 5 YL) 5 HYDROXY 5 (4 METHOXYPHENYL) 4 (3,4,5 TRIMETHOXYBENZYL) 2,5 DIHYDROFURAN 2 ONE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXYINDANE 2 CARBOXYLIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (6 CHLORO 1,3 BENZODIOXOL 5 YLMETHYL) INDOLE 2 CARBOXYLIC ACID; 4 (1,3 BENZODIOXOL 5 YL) 1 [[(DIBUTYLAMINO)CARBONYL]METHYL] 2 (4 METHOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 4 [2 (1,3 BENZODIOXOL 5 YL) 2 (4 ISOPROPYLPHENYLSULPHONAMIDO) 2 OXOETHOXY] 3 PROPYLBENZOATE DIPOTASSIUM; 5 (DIMETHYLAMINO) N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENE SULPHONAMIDE; 5,6,8,13 TETRAHYDRO 1,6,9,14 TETRAHYDROXY 3 (2 HYDROXYPROPYL) 7 METHOXY 8,13 DIOXO BENZO(A)NAPHTHACENE 2 CARBOXYLIC ACID; 5,6,8,13 TETRAHYDRO 1,6,9,14 TETRAHYDROXY 3 (2 HYDROXYPROPYL) 7 METHOXY 8,13 DIOXOBENZO[A]NAPHTHACENE 2 CARBOXYLIC ACID; ALPHA (4 CARBOXY 2 PROPYLPHENOXY) N (4 ISOPROPYLBENZENESULFONYL) 3,4 METHYLENEDIOXYPHENYLACETAMIDE; ATRASENTAN; BMS 182784; BOSENTAN; CGS 26393; CYCLO (DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL) [N [2 (BIPHENYL 4 YL) 1(S) (1H TETRAZOL 5 YL)ETHYL]AMINO]METHYLPHOSPHONIC ACID; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; L 751281; L 754142; N (4 CHLORO 3 METHYL 5 ISOXAZOLYL) 2 [2 (6 METHYL 1,3 BENZODIOXOL 5 YL) 1 OXOETHYL]THIOPHENE 3 SULPHONAMIDE; N [N[N [(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYLLEUCYL] 1 METHYL]TRYPTOPHYL 3 (2 PYRIDINYL)]ALANINE; PD 154804; SB 209598; SITAXSENTAN; TAK 044; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; GENE ISOLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; VASOCONSTRICTION;

EID: 0029922643     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-6147(96)30006-0     Document Type: Conference Paper

References (0)